Medtronic (MDT)
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
$94.17+1.15%
Close 2026-09-04 · 1-day change
NYSEHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · MDT
How strong the business is — where it ranks within its sector on capital efficiency and cash generation, and how well management has been executing.
How this business ranks within health care on a research-validated quality screen. As of 2026-09-04.
The screen ranks MDT against its sector on four durable signals: share dilution, return on capital, free-cash-flow yield, and FCF margin. Historically the highest-quality names tended toward better typical outcomes and fewer bad years over multi-year holds (strongest at three years, modest at one), and that pattern showed up even before the price moved. It characterizes business quality, not price direction.
Each leg is a sector-relative percentile (higher is better); 4 of 4 legs were available for this name. The composite is built from these four; the raw value follows each percentile for context.
A forward quality tilt, not a price prediction, and context for your own research rather than a recommendation. Not investment advice.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 1 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated strong grew net income 53% of the time over the next year (vs 41% for the rest of the cohort, n=9986).
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Met or beat guidance 0% of the last 3 guided quarters · -46.7% avg surprise
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Continue to drive mid-single to high-single digit organic revenue growth across key portfolios and franchises.
Stated as a priority in 8 of last 8 quarters. Medtronic reported FY26 organic revenue growth of 5.8%, improving from 4.9% in FY25, and guides FY27 organic growth to 6.75%-7.25%. The trajectory shows delivering sustained acceleration in organic revenue growth consistent with management's stated priority.
“Guiding to FY27 organic revenue growth of 6.75% to 7.25%.”
“FY26 organic revenue growth of 5.8%.”
“Reiterates FY26 organic revenue growth of approximately 5.5%.”
“Raised FY26 organic revenue growth guidance to approximately 5.5%.”
“Reiterates FY26 organic revenue growth of approximately 5%.”
“FY25 organic revenue growth of 4.9%.”
“FY25 organic revenue growth guidance reiterated at 4.75% to 5%.”
“Raised FY25 organic revenue growth guidance to 4.75% to 5%.”
Sustain and improve non-GAAP diluted EPS with operational leverage and margin discipline.
Stated as a priority in 8 of last 8 quarters. Medtronic's FY26 non-GAAP diluted EPS grew modestly to $5.53 from $5.49 in FY25. The company guides FY27 EPS to $5.90-$6.00, implying continued earnings leverage. The trajectory matches management's commitment to maintain and raise EPS guidance.
Focus on expanding key franchises such as Cardiac Ablation, Structural Heart, Neuromodulation, and Diabetes with new product introductions.
Stated as a priority in 6 of last 8 quarters. Key franchises like Cardiac Ablation Solutions grew by 78% in 2026-Q4 and Diabetes revenue increased 15%. New product launches such as Hugo robotic surgery and MiniMed 780G contributed to growth. The trajectory shows delivering strong growth in targeted franchises.
Continue to increase quarterly dividends annually, reflecting commitment to shareholder returns.
Stated as a priority in 4 of last 4 quarters. Medtronic increased its quarterly dividend to $0.72 in Q1 FY27, marking the 49th consecutive year of dividend increases. This consistent dividend growth reflects management's ongoing commitment to shareholder returns and is delivering as stated.
Manage and remediate IT security incident with external experts and ensure regulatory compliance.
Newly stated in 2026-Q3. Medtronic disclosed an IT security breach and has taken steps to contain the incident and engaged external cybersecurity experts. No financial impact or resolution milestones are reported yet, indicating early stage response and limited substantive delivery so far.
“Announced unauthorized third party accessed IT systems; activated incident response and engaged cybersecurity experts.”
Over the trailing year it converted 1.09x of net income into operating cash flow. Historically, Health Care names rated neutral grew net income 54% of the time over the next year (vs 43% for the rest of the cohort, n=3313).
Most sensitive to the broad stock market.
Not enough signal to read sensitivity to the US dollar, real (inflation-adjusted) rates, long-term interest rates, Fed net liquidity (low R² over the window).
12 material management or governance events in the past 24 months, led by executive changes. Historically, Health Care names rated neutral grew net income 53% of the time over the next year (vs 49% for the rest of the cohort, n=5275).
Not investment advice. As of 2026-09-04.
“Guiding FY27 diluted non-GAAP EPS of $5.90 to $6.00.”
“FY26 non-GAAP diluted EPS of $5.53, up 0.7%.”
“Reiterates FY26 diluted non-GAAP EPS guidance of $5.62 to $5.66.”
“Raised FY26 diluted non-GAAP EPS guidance to $5.62 to $5.66.”
“Raised FY26 diluted non-GAAP EPS guidance to $5.60 to $5.66.”
“FY25 non-GAAP diluted EPS of $5.49, up 6%.”
“FY25 diluted non-GAAP EPS guidance reiterated at $5.44 to $5.50.”
“Raised FY25 diluted non-GAAP EPS guidance to $5.44 to $5.50.”
“Cardiac Ablation Solutions revenue increased 78% globally, Diabetes business revenue increased 15%.”
“Cardiac Ablation Solutions revenue increased 80%, Diabetes revenue increased 8.3%.”
“Cardiac Ablation Solutions revenue increased 71%, Diabetes revenue increased 10.3%.”
“Cardiac Ablation Solutions revenue increased nearly 50%, Diabetes revenue increased 11.5%.”
“Cardiac Ablation Solutions Q4 revenue increased nearly 30%, Diabetes FY25 revenue increased 10.7%.”
“Cardiac Ablation Solutions revenue increased low-20s, Neuromodulation growth mid-teens.”
“Dividend for Q1 FY27 increased to $0.72 per share, 49th consecutive year of increases.”
“Dividend for Q1 FY26 increased to $0.71 per share, 48th consecutive year of increases.”
“Dividend for Q1 FY26 increased to $0.71 per share.”
“Dividend for Q1 FY26 increased to $0.71 per share.”